Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital

Study Overview
=================
Brief Summary
-----------------
AML in adults represents a group of heterogeneous diseases; the prognosis remains poor despite significant therapeutic advances in recent years. In order to optimize patient care, it is necessary to have real life data that exhaustively reports on the patients treated in our department. The objective of this study is: To describe the AML treated within the hematology department To optimize the management of patients with AML.

Detailed Description
-----------------
Current state of knowledge: Acute myeloblastic leukemia are the most common leukemias in adults. This pathology is very heterogeneous. It has a poor prognosis despite numerous therapeutic advances. The lack of randomized clinical trials can make certain treatment decisions difficult. In addition, patients with comorbidities or the elderly are most often excluded from these trials even though they represent a significant proportion of new diagnoses. Objectives: Primary objective Evaluate the overall survival of adult patients treated for AML in our hematology department at Saint-Antoine Hospital. Secondary objectives Evaluate early mortality at 30 days and 60 days post-induction Evaluate the CR/CRi rate after induction Evaluate the toxicity of the treatments Evaluate the relapse-free survival time Assess the prognostic value of JC-1 at diagnosis Evaluate the proportion of patients eligible for intensive treatment and/or allograft Evaluate the side effects of the treatments undertaken Describe the molecular and cytogenetic characteristics of hemopathies at diagnosis and at relapse Duration of study: Retrospective cohort (cohort A): patients diagnosed between junuary1,2010 and May 30,2022 Prospective cohort (cohort B): patients diagnosed between June 1, 2022 and December 31, 2023. A follow-up of 2 years will be necessary after the end of treatment. The end of follow-up is estimated at December 2025 for the entire cohort. Data collection: Collection of clinical and biological data in the patient's medical file via the Orbis software Population: Adult patients treated for AML at Saint-Antoine hospital

Official Title
-----------------
Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital

Conditions
-----------------
Acute Myeloid Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age :18 years and older Patients with AML Non objection to research Exclusion Criteria: Minor patients Acute promyelocytic leukemia (AML3)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 2 years after diagnosis | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 6 months after diagnosis | 
| Overall survival |  | 1 year after diagnosis | 
| Cytological remission rate |  | after the phase of induction up to 24 months | 
| Incomplete cytological remission rate |  | after the phase of induction up to 24 months | 
| Leukemia free survival rate |  | 24 months | 
| Side effects | according to the CTCAE v5.0 classification | 24 months | 
| the rate of patients receiving intensive treatment |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prognosis of Acute myeloblastic leukemia